SEHK:1643Pharmaceuticals
Modern Chinese Medicine Group (SEHK:1643) Half Year Profit Challenges Ongoing Loss Narrative
Modern Chinese Medicine Group (SEHK:1643) has opened FY 2025 with first half revenue of C¥64.8 million and basic EPS of C¥0.0041, setting a cautious tone against a recent history of mixed earnings. Over the past three reported half year periods, revenue has moved from C¥76.6 million in 1H 2024 to C¥137.4 million in 2H 2024 and C¥64.8 million in 1H 2025. Basic EPS shifted from a loss of C¥0.0114 in 1H 2024 to C¥0.0275 in 2H 2024 and C¥0.0041 in the latest half, leaving investors focused on how...